Startups

C2N Diagnostics

C2N Diagnostics develops and commercializes blood biomarker tests and laboratory services for Alzheimer’s disease and other neurodegenerative disorders. Its Precivity tests use high-resolution liquid chromatography and tandem mass spectrometry to measure proteins associated with brain amyloid pathology, helping clinicians evaluate patients with cognitive symptoms. The company also supplies biomarker measurements for clinical trials and researchers, and is developing tests for tau tangle pathology. Its laboratory in St. Louis serves clinical and research customers.

Team

Brianne PetersSenior Director, Commercial Operations

Catherine RegniSenior Director, Quality Assurance

Chris RathermelVice President, IT

Daniel ConnellSenior Director, Global Business Development and Strategy

David HoltzmanScientific Co-Founder; Board Member

Erin SmithSenior Project Manager, Design and Development

Fred MillerBoard Observer

Ilana FogelmanCo-Founder and Senior Advisor for Medical Innovation

Jason WhealeSenior Director, Information Technology Quality Assurance, Compliance and Data Privacy

Joel B. BraunsteinCo-Founder and Chief Executive Officer; Board Member

Joni HendersonSenior Director, Corporate Communications

Justine CoppingerVice President, Medical Affairs

Kristopher KirmessSenior Director, Clinical Chemistry and Commercial Assays

Mark MonaneSenior Medical Advisor

Mary HolubaschDirector, Clinical Supervisor, Lead Technologist

Matthew MeyerSenior Director, Research & Development

Micah OnixtExecutive Vice President, General Counsel, Privacy and Compliance Officer, and Corporate Secretary

Michael GoldblattBoard Member

Patricia DeSimoneAssociate General Counsel & Vice President of Human Resources

Philip VergheseSenior Vice President, R&D and Laboratory Operations

Rachel ResnickSenior Director and Controller

Rahul ChaudharyExecutive Vice President, Global Strategy and Commercialization

Randall BatemanScientific Co-Founder; Board Member

Scott HarpstriteDirector, Laboratory Operations

Tim ReillyVice President, Finance

Tim WestVice President, Research and Development

Venky VenkateshSenior Director, Project Management

Investments

$10M2025-03-13	Samsung Venture Investment Corporation
$15M2024-09-30	GHR Foundation
$—2024-09-25	Alzheimer's Drug Discovery Foundation
$—2024-03-06	0 participations
$15M2023-02-16	GHR Foundation

team@apexlogos.ai21 hours ago
C2N’s public directories name 23 leaders and four additional board representatives, for 27 unique people. CEO Joel B. Braunstein is also a board member; David Holtzman and Randall Bateman are scientific co-founders and board members. Fred Miller appears in the current board directory, but his explicit 2023 appointment was as Board Observer; no voting-member promotion is inferred. GHR’s February2023 and September2024 program-related investments were USD15m each. Its initial early2020 USD20m investment still needs an exact announcement date. The March2025 Samsung investment was USD10m collectively, with the explicitly named existing Samsung Venture Investment Corporation linked; its fund and other corporate participants need full profiles. Eisai Inc’s March2024 investment was up to USD15m and ADDF’s September2024 Diagnostics Accelerator funding was up to USD7.025m; exact amounts remain unknown. The latter is linked to existing ADDF3232, while Eisai Inc is distinct from EisaiInnovation6022. These are separate financings; no prior backer is automatically assigned to a later investment. The description explains mass spectrometry and Alzheimer’s biomarkers without inferring commercial availability from FDA clearance.